Immune checkpoint inhibitors (ICIs) are currently a first-line treatment option for clear cell
renal cell carcinoma (ccRCC). However, recent clinical studies have shown that a large …

Simple Summary Clear cell renal cell carcinomas (ccRCC) have several distinct
immunological features, including a high degree of immune infiltration and relatively low …

Clear cell renal cell carcinoma (ccRCC) is a type of kidney cancer that arises from the cells
lining the tubes of the kidney. The tumor immune microenvironment (TIME) of ccRCC is a …

Simple Summary In recent years, the therapeutic armamentarium of mccRCC has changed
dramatically with the emergence of targeted therapy and immune checkpoint inhibitors, used …

Simple Summary Until recently, checkpoint inhibitors have largely been reserved for the
metastatic disease space in clear cell renal cell carcinoma (ccRCC). Over the last several …

The prognosis for advanced clear cell renal cell carcinoma (ccRCC) is not satisfactory, even
though its treatment has evolved rapidly over the past 20 years. Systemic ccRCC treatment …

Simple Summary Immunotherapy-based combinations represent the front-line standard of
care for metastatic clear cell renal cell carcinoma (mccRCC) patients. These combinations …

Background Immunotherapy has revolutionized the treatment of clear cell renal cell
carcinoma (ccRCC). However, the therapy is constrained by drug resistance. Therefore …

Renal clear cell carcinoma (RCC) is the most common type of kidney cancer and has a high
propensity for metastasis. While treatment with immune checkpoint inhibitors, such as anti …

Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer and has
strong immunogenicity. A systematically investigation of the tumor microenvironment (TME) …